Expression levels of the runt-related transcription factor�1 and�3 genes in the development of acute myeloid leukemia

Abstract

Abstract. The aim of the present study was to evaluate the mRNA expression level of the runt-related transcription factor 1 (RUNX1) and runt-related transcription factor 3 (RUNX3) genes in patients with acute myeloid leukemia (AML). The etiology of AML is not yet fully known, but certain genetic factors may contribute to its manifestation. The RUNX1 and RUNX3 genes have been demonstrated to serve a role in the transcription process. The group investigated in the present study included 43 patients diagnosed with AML, and the relative RUNX1 and RUNX3 expression levels were determined using reverse transcription-quantitative polymerase chain reaction. The results indicated that RUNX1 and RUNX3 expression was associated with clinicopathological features, including sex and mortality risk. Expression levels of the RUNX1 gene were higher and more variable among females (P=0.044), and mortality was more frequent among patients with a higher RUNX3 expression level (P=0.036). The data obtained from the present study suggested that RUNX3 expression may have potential value as a prognostic factor; furthermore, sex is potentially a factor that may affect the difference in RUNX1 gene expression level among females and males. Further analyses in this field will aid in the identification and elucidation of the molecular basis of leukemia.

Runx1 Gene in Acute Myeloid Leukemia: Expression Level Significance and Impact on Clinical Features

“…However, in this study, we did not nd any correlation between RUNX1 expression and FAB classi cation, OS, and PFS (P = 0.348, P = 0.804, P = 0.314, respectively). This is similar to KRYGIER A et al, who concluded that high expression of RUNX1 has no relation to FAB classi cation of AML and mortality [47]. Our study found no associations between age, TLC, Hb, PLT, peripheral and bone marrow blasts and different ELN genetic groups and the level of RUNX1 expression.…”

“…Furthermore, we observed a signi cantly higher RUNX1 expression in male patients (p = 0.046). This result was in contrast to the ndings of KRYGIER A et al who reported in his study on 43 polish De Novo AML cases using RT qPCR analysis technique that RUNX1 signi cantly expressed in females [47]. This disagreement may be due the difference in sample size or could be due to racial difference.…”

“…Translocationsand mutations of RUNX1 gene locus were reported tocauseincrease or decrease in its functionand to induce leukemia [43][44][45]. To the best of our knowledge, our study was the rst to present different expression levels of RUNX1 gene in Egyptian population, as the previous human studies was conducted on Chinese and polish populations [47,49].…”

Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development

“…2 a). Moreover, using previously published data [ 26 ] in the same patient cohort, the connection between expression levels of CEBPA and c-MYC and RUNX1 and RUNX3 expression level was analyzed. CEBPA expression level was not significantly associated with either RUNX1 or RUNX3 expression level (r S =0.270, p=0.0875 and r S =0,013, p=0.9366, Fig.…”

“…Recently, Weng et al demonstrated that GM-CSF attenuates MYC-associated gene signatures in t (8;21) (RUNX1-ETO) leukemia cells, but not in control cells by restoring the expression of a subset of MYC-repressed targets (e.g. CEBPA) , which promote a myeloid differentiation and apoptosis [ 26 ]. MYC and RUNX1 with two other factors, SP1 and GATA2, form multi-protein transcription complex which activates expression of SET , encoding important oncoprotein for AML development.…”